LYRA — Lyra Therapeutics Share News
0.000.00%
Last trade - 00:00- $0.34m
- -$15.56m
- $0.40m
Lyra Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Lyra Therapeutics Reports Fourth Quarter And Full Year 2021 Financial Results And Provides Corporate Update
Lyra Therapeutics Inc expected to post a loss of 79 cents a share - Earnings Preview
Brief: Lyra Therapeutics Announces First Patient Dosed In Clinical Trial Of Lyr-210
Brief: Lyra Therapeutics Announces Initiation Of Lyr-210 Pivotal Phase 3 Enlighten Program In Surgically Naïve Chronic Rhinosinusitis Patients
Lyra Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Lyra Therapeutics Posts Quarterly Loss Per Share Of $0.85
Brief: Lyra Therapeutics Inc Wins Award At The 67Th Annual Meeting Of The American Rhinologic Society
Brief: Lyra Therapeutics Publishes Positive Lantern Results In The International Forum Of Allergy & Rhinology
U.S. STOCKS ON THE MOVE-Verastem, Tesla, Synlogic, U.S. banks
Brief: Lyra Therapeutics Appoints Jason Cavalier As CFO
Brief: Lyra Therapeutics Announces Preclinical Pharmacokinetics And Drug Release Characterization For Xtreo Technology Platform
Lyra Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Lyra Therapeutics Inc expected to post a loss of 59 cents a share - Earnings Preview
Lyra Therapeutics Inc expected to post a loss of 59 cents a share - Earnings Preview
Lyra Therapeutics Inc expected to post a loss of 59 cents a share - Earnings Preview
Lyra Therapeutics rises after positive safety data on sinus drug
Brief: Lyra Therapeutics Announces Positive Topline Results Of Pharmacokinetic Study Of Lyr-210 In Patients With Chronic Rhinosinusitis
Lyra Therapeutics: Up on FDA feedback for sinus drug